COSMO Pharmaceuticals N.V.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands (Kingdom of the)
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focusing on innovative therapies for gastrointestinal diseases and specialty treatments.
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-30 02:00 |
Declaration of Voting Results & Voting Rights Announcements
Voting results of Cosmo’s 2025 AGM
|
English | 5.1 KB | |
| 2025-05-30 02:00 |
Declaration of Voting Results & Voting Rights Announcements
Ergebnisse der Generalversammlung 2025 von Cosmo
|
German | 5.4 KB | |
| 2025-05-05 02:00 |
Inside Information Statement
Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Wee…
|
English | 6.4 KB | |
| 2025-05-05 02:00 |
Inside Information Statement
Cosmo präsentiert strategische Innovationsagenda für KI und Gastroenterologie a…
|
German | 7.1 KB | |
| 2025-05-02 02:00 |
Inside Information Statement
Cosmo Announces EU MDR Certification for Endovision’s Cerebro, expanding its re…
|
English | 10.3 KB | |
| 2025-05-02 02:00 |
Inside Information Statement
Cosmo gibt EU-MDR-Zertifizierung für Cerebro von Endovision bekannt und erweite…
|
German | 11.4 KB | |
| 2025-04-01 02:00 |
Inside Information Statement
Cosmo appoints Federico Sommariva as Chief Legal Counsel
|
English | 5.2 KB | |
| 2025-04-01 02:00 |
Inside Information Statement
Cosmo ernennt Federico Sommariva zum Chief Legal Counsel
|
German | 5.9 KB | |
| 2025-03-06 01:00 |
Earnings Release
Cosmo Pharmaceuticals Delivers Record 2024 Results – Completes Phase III Enroll…
|
English | 28.1 KB | |
| 2025-03-06 01:00 |
Earnings Release
Cosmo Pharmaceuticals mit Rekordergebnis 2024 – Abschluss der Phase-III-Rekruti…
|
German | 30.4 KB | |
| 2025-02-12 01:00 |
Inside Information Statement
Cosmo to host Investor Day on April 9, 2025
|
English | 5.3 KB | |
| 2025-02-12 01:00 |
Inside Information Statement
Cosmo lädt am 9. April 2025 zum Investorentag ein
|
German | 5.7 KB | |
| 2025-02-11 01:00 |
Inside Information Statement
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Acro…
|
English | 8.5 KB | |
| 2025-02-11 01:00 |
Board/Management Change
Cosmo ernennt Andrea Cherubini zum Chief AI Officer, um die KI-Expansion im ge…
|
German | 9.0 KB | |
| 2025-02-10 01:00 |
Regulatory News Service
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi® for Treatment of Acne
|
English | 10.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
OncoZenge AB | Sweden | ONCOZ | |
|
Orexo | Sweden | ORX | |
|
Orion Oyj | Finland | ORNAV | |
|
PAION AG | Germany | PA8 | |
|
PEPTONIC Medical AB | Sweden | PMED | |
|
Pharmanutra | Italy | PHN | |
|
PharmaSGP Holding SE | Germany | PSG | |
|
Pharmena S.A. | Poland | PHR |